Clinical Efficacy of Recombinant Human Brain Natriuretic Peptide Combined with Bisoprolol in the Treatment of Patients with Ischemic Cardiomyopathy and its Effect on CITED2, miR-182 and HIF-1
ZHOU Fang-zhou, ZHAO Qing-yan, WANG Ai-hong
Shandong Provincial Third Hospital,Jinan Shandong 250031
Abstract：【Objective】To investigate the clinical efficacy of recombinant human brain natriuretic peptide combined with bisoprolol in the treatment of patients with ischemic cardiomyopathy (ICM) and its effect on the levels of microRNA-182 (miR-182), protein trans acting factor (CITED2) and hypoxia inducible factor-1 (HIF-1). 【Methods】A total of 128 ICM patients treated in the Third Hospital of Shandong Province from October 2018 to October 2020 were prospectively selected and divided into observation group and control group according to the random number table method, with 64 cases in each group. On the basis of routine treatment, the control group was treated with bisoprolol, and the observation group was treated with recombinant human brain natriuretic peptide on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were compared, and the levels of serum cardiomyocyte apoptosis index [soluble apoptosis related factor (sFas), soluble apoptosis related factor ligand (sFasL)], markers of myocardial ischemia injury[troponin T (cTnT), myoglobin (Mb), creatine kinase isoenzyme (CK-MB)] and CITED2, miR-182 and HIF-1 were compared before and after treatment.【Results】After one month of treatment, the total effective rate in the observation group was higher than that in the control group (P<0.05); The levels of serum sFas, sFasL, cTnT, Mb and CK-MB in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05); The levels of serum CITED2 in the two groups were higher than those before treatment, and the levels of miR-182 and HIF-1 were lower than those before treatment, and the difference between the two groups was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was higher than that in the control group, but the difference was not statistically significant (P>0.05). 【Conclusion】Recombinant human brain natriuretic peptide combined with bisoprolol is effective in the treatment of ICM patients. It can enhance the ability of myocardial anti hypoxia and ischemia, inhibit cardiomyocyte apoptosis, and has good safety.
周方舟, 赵庆燕, 王爱红. 重组人脑利钠肽联合比索洛尔治疗缺血性心肌病患者的临床疗效及对CITED2、miR-182、HIF-1水平的影响[J]. 医学临床研究, 2022, 39(10): 1550-1552.
ZHOU Fang-zhou, ZHAO Qing-yan, WANG Ai-hong. Clinical Efficacy of Recombinant Human Brain Natriuretic Peptide Combined with Bisoprolol in the Treatment of Patients with Ischemic Cardiomyopathy and its Effect on CITED2, miR-182 and HIF-1. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1550-1552.
2022, Vol. 39 
